Lexology January 13, 2026
Christoph W.G. Engeler Partner Private Capital’s Evolving Playbook for Healthcare and Life Sciences Private capital is flowing into the sector earlier, targeting younger companies with built-in platform potential.
Key Takeaways • Continuation vehicles have become a popular mechanism for providing liquidity in a tight exit market. • Investors are looking for real-world, measurable AI use cases, with a focus on drug discovery and optimizing the journey from molecule to market. • Biotech adjacencies and rare disease therapeutics offer strong pricing power, regulatory incentives, and scalable platforms.
Private capital is poised to remain a driving force in healthcare and life sciences, even as the sector navigates a more complex and competitive environment. After a record-setting surge in 2024 — when global...
Today's Sponsors
Today's Sponsor